A simple breath may contain more information about human health than previously imagined. Researchers are increasingly studying exhaled breath as a source of biological markers that could help monitor metabolism, identify disease-related changes, and support non-invasive diagnostics.
Artificial intelligence (AI) breath analyzers combine advanced sensors with machine learning algorithms to analyze compounds present in exhaled air. Although the technology remains largely in the research and validation stage, growing evidence suggests that breath analysis could become an important tool in the future of personalized healthcare.
AI breath analyzers are devices that examine volatile organic compounds (VOCs) found in exhaled breath. VOCs are chemical compounds produced by normal metabolic processes and biological activity within the body.
After collecting a breath sample, the device uses sensors or analytical technologies to detect VOC patterns. Machine learning algorithms then analyze these patterns to identify associations with specific physiological or pathological conditions.
Researchers often refer to this field as breathomics, which focuses on studying the molecular composition of exhaled breath and its relationship to health and disease.
Traditional diagnostic methods often require blood samples, imaging procedures, or invasive testing. Breath analysis offers a faster and non-invasive alternative that can be repeated frequently without discomfort.
A 2023 review titled "Breath Volatile Organic Compounds (VOCs) as Biomarkers for Human Health and Diseases" highlighted that VOCs may serve as valuable biomarkers for a range of health conditions. The authors noted that breath analysis has attracted significant interest because it is rapid, painless, and potentially cost-effective.
Researchers believe that metabolic changes occurring within the body may alter the composition of exhaled VOCs, creating detectable chemical signatures linked to specific diseases.
One of the biggest challenges in breathomics is interpreting the large number of compounds present in every breath sample. Human breath can contain hundreds of VOCs, making manual analysis difficult.
Artificial intelligence helps researchers process complex datasets and identify patterns that may be associated with disease or physiological states. Machine learning models can analyze breath profiles and classify samples more efficiently than traditional approaches.
As a result, AI is becoming an increasingly important component of next-generation breath analysis technologies.
Lung cancer is among the most extensively studied applications of AI-assisted breath analysis.
In 2024, Manuel Vinhas and colleagues published the study "AI Applied to Volatile Organic Compound (VOC) Profiles from Exhaled Breath Air for Early Detection of Lung Cancer" in the journal Cancers. The researchers used machine learning models to analyze VOC patterns in breath samples and explored their potential role in distinguishing lung cancer cases from healthy controls. The study demonstrated the growing promise of combining AI with breathomics for non-invasive cancer screening.
In 2025, Bernardo S. Raimundo and colleagues published "Breath Insights: Advancing Lung Cancer Early-Stage Detection Through AI and Volatile Organic Compound Analysis." The study further investigated the relationship between VOC profiles and artificial intelligence for lung cancer detection, highlighting the potential of breath-based screening approaches.
Importantly, researchers emphasize that these technologies remain investigational and require further validation before widespread clinical adoption.
Many AI breath analyzers rely on electronic nose, or eNose, technology.
An eNose uses an array of sensors to detect overall chemical patterns rather than measuring a single molecule. The collected data are then analyzed using machine learning algorithms to identify characteristic breath signatures.
A systematic review and meta-analysis titled "Accuracy of the Electronic Nose Breath Tests in Clinical Diagnosis" evaluated the performance of eNose technologies across multiple clinical applications. The authors concluded that electronic noses show considerable promise, while also emphasizing the need for additional validation studies.
Researchers are exploring breath analysis across several areas of healthcare.
Scientists have investigated VOC patterns associated with asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Recent systematic reviews suggest that breath analysis may help differentiate respiratory disease states, although further clinical validation is needed.
Breath-based diagnostics gained attention during the COVID-19 pandemic. Meta-analyses evaluating VOC-based breath testing have reported promising diagnostic performance for identifying infection-related signatures in exhaled breath.
Researchers are also studying how metabolic processes influence breath composition. Changes in VOC profiles may provide insights into energy metabolism, nutritional status, and broader physiological function.
Despite encouraging research findings, several challenges remain.
Different studies often use different sensors, sampling techniques, and analytical methods, making it difficult to compare results directly.
Diet, medications, smoking habits, air quality, and oral health can all affect VOC profiles and potentially influence test results.
Most breathomics studies involve relatively limited sample sizes. Researchers continue to call for larger, multicenter clinical trials to validate findings and establish
AI-powered breath analyzers offer a glimpse into a future where health monitoring could become faster, easier, and less invasive. By analyzing volatile organic compounds in exhaled breath, researchers hope to uncover biological signals linked to cancer, respiratory diseases, infections, and metabolic health.
References:
1. Moura, Pedro Catalão, Maria Raposo, and Valentina Vassilenko. 2023. “Breath Volatile Organic Compounds (VOCs) as Biomarkers for the Diagnosis of Pathological Conditions: A Review.” Biomedical Journal 46 (4): 100623. https://www.sciencedirect.com/science/article/pii/S2319417023000604
2. Liu, Yi, Yiyang Li, Xiangdong Wang, and colleagues. “Electronic Nose and Breathalyzer Technologies for Noninvasive Disease Detection: Current Advances and Future Perspectives.” Biosensors 14, no. 6 (2024): 282.
https://pubmed.ncbi.nlm.nih.gov/38927906/
3. Kumi, E., M. O. Boadi, E. K. Amankwah, and A. O. Boateng. “A Low-Cost Artificial Intelligence Powered Breath Analyzer for Chronic Obstructive Pulmonary Disease Screening in Resource-Limited Settings.” PLOS Digital Health 5, no. 5 (2026): e0000894.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12961126/
4. Raimundo, Bernardo S., Pedro M. Leitão, Pedro D. Vaz, and colleagues. “Breath Insights: Advancing Lung Cancer Early-Stage Detection Through AI Algorithms in Non-Invasive VOC Profiling Trials.” Cancers 17, no. 10 (2025): 1685.
https://www.mdpi.com/2072-6694/17/10/1685